Novo Nordisk A/S
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVO research report →
Companywww.novonordisk.com
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
- CEO
- Maziar Mike Doustdar
- IPO
- 1981
- Employees
- 77,406
- HQ
- Bagsvaerd, DK
Price Chart
Valuation
- Market Cap
- $200.28B
- P/E
- 10.51
- P/S
- 3.91
- P/B
- 6.31
- EV/EBITDA
- 7.65
- Div Yield
- 4.06%
Profitability
- Gross Margin
- 81.85%
- Op Margin
- 45.30%
- Net Margin
- 37.20%
- ROE
- 66.36%
- ROIC
- 32.20%
Growth & Income
- Revenue
- $309.06B · 6.43%
- Net Income
- $102.43B · 1.43%
- EPS
- $23.06 · 1.72%
- Op Income
- $127.66B
- FCF YoY
- -58.38%
Performance & Tape
- 52W High
- $81.44
- 52W Low
- $35.12
- 50D MA
- $40.18
- 200D MA
- $49.10
- Beta
- 0.35
- Avg Volume
- 20.56M
Get TickerSpark's AI analysis on NVO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NVO Coverage
We haven't published any research on NVO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NVO Report →